Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 19/20 | 0.64 |
| ▸ | MMP1 | P03956 | 2/20 | 0.64 |
| ▸ | MMP9 | P14780 | 17/20 | 0.47 |
| ▸ | MMP14 | P50281 | 14/20 | 0.45 |
| ▸ | MMP3 | P08254 | 8/20 | 0.45 |
| ▸ | MMP8 | P22894 | 5/20 | 0.45 |
| ▸ | MMP7 | P09237 | 3/20 | 0.45 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12717348 | 0.87 | MMP2 (0.69) | MMP2MMP1MMP9MMP14MMP3 | |
| SCHEMBL10187455 | 0.85 | MMP2 (0.60) | MMP2MMP1MMP9MMP14MMP3 | |
| SCHEMBL4292169 | 0.82 | MMP2 (0.67) | MMP2MMP1MMP9MMP14MMP3 | |
| SCHEMBL14727897 | 0.82 | MMP2 (0.71) | MMP2MMP1MMP9MMP14MMP3 | |
| SCHEMBL10187454 | 0.80 | MMP2 (0.57) | MMP2MMP1MMP9MMP14MMP3 | |
| SCHEMBL10187462 | 0.79 | MMP2 (0.67) | MMP2MMP1MMP9MMP14MMP3 | |
| SCHEMBL10238689 | 0.79 | MMP2 (0.56) | MMP2MMP1MMP9MMP14MMP3 | |
| SCHEMBL314080 | 0.78 | MMP2 (1.00) | MMP2MMP1MMP9MMP14MMP3 | |
| SCHEMBL314470 | 0.78 | MMP2 (0.61) | MMP2MMP1MMP9MMP14MMP3 | |
| SCHEMBL10187427 | 0.77 | MMP2 (0.60) | MMP2MMP1MMP9MMP14MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9867805-B2 | Gelatinase inhibitors and prodrugs | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2018-01-16 | — | — | US | disclosed |
| US-20160346247-A1 | GELATINASE INHIBITORS AND PRODRUGS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2016-12-01 | — | — | US | disclosed |
| US-9321754-B2 | Gelatinase inhibitors and prodrugs | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2016-04-26 | — | — | US | disclosed |
| US-20150093372-A1 | GELATINASE INHIBITORS AND PRODRUGS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2015-04-02 | — | — | US | disclosed |
| US-8937151-B2 | Gelatinase inhibitors and prodrugs | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2015-01-20 | — | — | US | disclosed |
| US-20130052184-A1 | GELATINASE INHIBITORS AND PRODRUGS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130052184-A1 | GELATINASE INHIBITORS AND PRODRUGS | MMP14, MMP9, MMP10 | MMP2 15/4885MMP1 17/4885MMP9 2/4885 |
| US-20160346247-A1 | GELATINASE INHIBITORS AND PRODRUGS | MMP14, MMP9, MMP10 | MMP2 15/4885MMP1 17/4885MMP9 2/4885 |
| US-20150093372-A1 | GELATINASE INHIBITORS AND PRODRUGS | MMP14, MMP9, MMP10 | MMP2 15/4885MMP1 17/4885MMP9 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.